User: Guest  Login
More Searchfields
Simple search
Title:

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.

Document type:
Journal Article; Review
Author(s):
Ettl, Johannes
Abstract:
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed.
Journal title abbreviation:
Breast Care (Basel)
Year:
2016
Journal volume:
11
Journal issue:
3
Pages contribution:
174-6
Language:
eng
Fulltext / DOI:
doi:10.1159/000447417
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/27493616
Print-ISSN:
1661-3791
TUM Institution:
Frauenklinik und Poliklinik
 BibTeX